Brii Biosciences Limited (2137.HK) HKSE
1.08
-0.03(-2.70%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Brii Biosciences Limited
Sector
Healthcare
Industry
Biotechnology
Employees
98
First IPO Date
July 13, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Zhi Hong | Co-founder, Executive Chairman of the Board & Chief Executive Officer | 11.68M | 1963 |
| Ankang Li | COO, Joint Secretary & Executive Director | 6.37M | 1979 |
| Haifeng Cao | Head of China Development | 0 | 1973 |
| Qing Zhu | Head of Pre-clinical Sciences and Translational Research | 0 | 1968 |
| Susannah Cantrell | Chief Business Officer | 0 | 1969 |
| Eleanor de Groot | Chief Technology Officer | 0 | 1969 |
| Sarah Qiu | Associate Director of Investor Relations | 0 | N/A |
| David Margolis | Chief Medical Officer | 0 | 1975 |
| Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources | 0 | 1976 |
| Wing Tsz FCIS | Joint Company Secretary | 0 | 1970 |
| Brian Alvin Johns | Chief Scientific Officer | 0 | 1971 |
Description
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
